Results 251 to 260 of about 110,208 (302)

Defining the heterogeneous molecular landscape of lung cancer cell responses to epigenetic inhibition. [PDF]

Commun Biol
Lin C, Sniezek CM, McGann CD, Karki R, Giglio RM, Garcia BA, McFaline-Figueroa JL, Schweppe DK.   +7 more
europepmc   +1 more source

Epigenetic and Transcriptomic Pathways Underlying Animal Models of Cognitive and Psychiatric Disorders: A Scoping Review. [PDF]

Curr Issues Mol Biol
Rathored J, Pal A, Sai Painkra D.
europepmc   +1 more source

CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease. [PDF]

Alzheimers Res Ther
Lu W, Kawatani K, Ren Y, Nambara T, Jia L, Jeevaratnam S, Lee E, Martinez PR, Izhar T, Wang N, Raulin AC, Wszolek ZK, Bu G, Kanekiyo T, Li Y.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Inside HDAC with HDAC inhibitors

European Journal of Medicinal Chemistry, 2010
Histone deacetylase inhibitors are a large group of diverse molecules intrinsically able to inhibit cell proliferation in various cancer cell lines. Their apoptotic effects have been linked to the modulation in the expression of several regulatory tumor suppressor genes caused by the modified status of histone acetylation, a key event in chromatin ...
Philippe Bertrand
exaly   +3 more sources

NO-HDAC dual inhibitors

European Journal of Medicinal Chemistry, 2022
HDAC inhibitors and NO donors have both demonstrated independently broad therapeutic potential in a variety of diseases. Borretto et al. presented the topic of NO-HDAC dual inhibitors for the first time in 2013 as an attractive new topic. Here we collected the general structure of all synthesized NO-HDAC dual inhibitors, lead compounds, synthesis ...
Negar Omidkhah, Razieh Ghodsi
exaly   +3 more sources

The application of PROTAC in HDAC

European Journal of Medicinal Chemistry, 2023
Inducing protein degradation by proteolysis targeting chimera (PROTAC) has provided great opportunities for scientific research and industrial applications. Histone deacetylase (HDAC)-PROTAC has been widely developed since the first report of its ability to induce the degradation of SIRT2 in 2017.
Shaoting Chen, Yuxiang Zheng, Benji Liang, Yudong Yin, Jian Yao, Quande Wang, Yanghan Liu, Nouri Neamati   +7 more
openaire   +2 more sources

Inside HDACs with more selective HDAC inhibitors

European Journal of Medicinal Chemistry, 2016
Inhibitors of histone deacetylases (HDACs) are nowadays part of the therapeutic arsenal mainly against cancers, with four compounds approved by the Food and Drug Administration. During the last five years, several groups have made continuous efforts to improve this class of compounds, designing more selective compounds or compounds with multiple ...
Joelle Roche, Philippe Bertrand
exaly   +3 more sources

HDAC Inhibitors

2016
Lysine acetylation in proteins is one of the most abundant posttranslational modifications in eukaryotic cells. The dynamic homeostasis of lysine acetylation and deacetylation is dictated by the action of histone acetyltransferases (HAT) and histone deacetylases (HDAC).
Heidi, Olzscha, Mina E, Bekheet, Semira, Sheikh, Nicholas B, La Thangue   +3 more
openaire   +2 more sources

HDAC inhibitors in HIV

Immunology & Cell Biology, 2011
Combination antiretroviral therapy (cART) has led to a very substantial reduction in morbidity and mortality in HIV‐infected patients; however, cART alone is unable to cure HIV and therapy is lifelong. Therefore, a new strategy to cure HIV is urgently needed.
Wightman, F, Ellenberg, P, Churchill, M, Lewin, SR   +3 more
openaire   +3 more sources